{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:42:47Z","timestamp":1793072567961,"version":"4.5.0"},"reference-count":50,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:sec id=\"ab-doi250022-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Patients with atopic dermatitis (AD) have been reported to develop psoriasis during dupilumab treatment. Whether this represents a true association or an incidental event remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi250022-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare psoriasis risk in patients with AD who are prescribed dupilumab vs other systemic agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi250022-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This population-based retrospective cohort study with 3-year follow-up, with analyses completed on October 19, 2024, included 214\u202f430 adult patients with AD  from the TriNetX Global Collaborative Network. Individuals newly prescribed dupilumab (dupilumab cohort) and those newly prescribed the other systemic agents without dupilumab exposure (control cohort) were included. Propensity score matching at a 1:1 ratio based on age, sex, race, comorbidities, laboratory measurements, and prior medications was conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi250022-7\">\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>Dupilumab vs the other systemic agents (corticosteroids, methotrexate, cyclosporine, azathioprine, or mycophenolate mofetil).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi250022-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary outcome was incident psoriasis. Cumulative incidence was assessed using Kaplan-Meier plots and risks via Cox regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi250022-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After matching, each cohort comprised 9860 patients, with 10\u202f891 female individuals (55.2%), a mean (SD) age of 44.8 (20.3) years, 3582 African American or Black individuals (18.2%), 2004 Asian individuals (10.2%), and 9901 White individuals (50.2%). The 3-year cumulative psoriasis incidence was higher in the dupilumab cohort than the control cohort (2.86% vs 1.79%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001). The number needed to harm for psoriasis was 94 for dupilumab vs the other systemic agents. The dupilumab cohort showed an increased risk for psoriasis (hazard ratio [HR], 1.58; 95% CI, 1.25-1.99), although the risk for psoriatic arthritis was not significant (HR, 1.97; 95% CI, 0.75-5.18). This increased risk was also observed in various AD subgroups, including those without atopic comorbidities (HR, 1.42; 95% CI, 1.06-1.89) or with pretreatment immunoglobulin E levels less than 0.048 mg\/dL (to convert to mg\/L, multiply by 10; HR, 1.59; 95% CI, 1.26-2.01). The association between dupilumab and psoriasis was further supported by validation in patients with asthma without AD (HR, 2.13; 95% CI, 1.38-3.31).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi250022-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>The results of this cohort study suggest that patients with AD who were prescribed dupilumab exhibited a higher relative risk of developing psoriasis compared with those receiving other systemic agents. Given an estimated number needed to harm of 94, the absolute risk may have limited clinical relevance and should be weighed against dupilumab\u2019s established efficacy in treating AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamadermatol.2025.1578","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T11:01:06Z","timestamp":1750244466000},"page":"813","source":"Crossref","is-referenced-by-count":40,"title":["Psoriasis Risk in Patients With Atopic Dermatitis Treated With Dupilumab"],"prefix":"10.1001","volume":"161","author":[{"given":"Teng-Li","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Dermatology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan"},{"name":"PhD Program of Interdisciplinary Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsuan","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Chung Shan Medical University Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Sheng","family":"Fan","sequence":"additional","affiliation":[{"name":"Division of Chest Medicine, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Kuei","family":"Juan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Taichung Veterans General Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ju","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Taichung Veterans General Hospital, Taichung, Taiwan"},{"name":"Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan"},{"name":"Faculty of Medicine and Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Ying","family":"Wu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan"},{"name":"Institute of Biomedical Informatics, National Yang Ming Chiao Tung University, Taipei, Taiwan"},{"name":"Division of Translational Research, Taipei Veterans General Hospital, Taipei, Taiwan"},{"name":"College of Public Health, China Medical University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"24","key":"doi250022r1","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"issue":"10086","key":"doi250022r2","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"doi250022r3","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/bjd.16156","article-title":"Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9).","volume":"178","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"issue":"5","key":"doi250022r4","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.jaad.2021.01.012","article-title":"Facial and neck erythema associated with dupilumab treatment: a systematic review.","volume":"84","author":"Jo","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi250022r5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jaad.2024.03.039","article-title":"Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.","volume":"91","author":"Hasan","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi250022r6","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jaad.2021.05.013","article-title":"Development of psoriasis during treatment with dupilumab: a systematic review.","volume":"86","author":"Brumfiel","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi250022r7","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1159\/000530608","article-title":"Dupilumab-associated psoriasis and psoriasiform manifestations: a scoping review.","volume":"239","author":"Su","year":"2023","journal-title":"Dermatology"},{"issue":"19","key":"doi250022r8","doi-asserted-by":"publisher","first-page":"6291","DOI":"10.3390\/jcm12196291","article-title":"\u201cDe novo\u201d psoriasis and relapse of psoriasis induced by dupilumab: three new cases and review of the literature.","volume":"12","author":"Trave","year":"2023","journal-title":"J Clin Med"},{"issue":"3","key":"doi250022r9","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.alit.2020.02.004","article-title":"An asthmatic case of psoriasiform eruption caused by administration of dupilumab.","volume":"69","author":"Matsuda","year":"2020","journal-title":"Allergol Int"},{"issue":"6","key":"doi250022r10","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14169","article-title":"Psoriasis onset under dupilumab treatment in two patients affected by atopic dermatitis and one patient affected by alopecia areata: clinical and dermoscopic patterns.","volume":"33","author":"D\u2019Ambra","year":"2020","journal-title":"Dermatol Ther"},{"issue":"1","key":"doi250022r11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/1346-8138.16595","article-title":"Dupilumab-induced skin-associated side effects in patients with chronic rhinosinusitis with nasal polyposis.","volume":"50","author":"Chromy","year":"2023","journal-title":"J Dermatol"},{"issue":"5","key":"doi250022r12","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1111\/bjd.18031","article-title":"Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series.","volume":"181","author":"Willsmore","year":"2019","journal-title":"Br J Dermatol"},{"issue":"10","key":"doi250022r13","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/art.42558","article-title":"Characterization of a musculoskeletal syndrome of enthesitis and arthritis in patients with atopic dermatitis treated with dupilumab, an interleukin\u20134\/13 inhibitor.","volume":"75","author":"Hughes","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"doi250022r14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jdcr.2021.12.011","article-title":"Review of dupilumab-associated inflammatory arthritis: an approach to clinical analysis and management.","volume":"21","author":"Jay","year":"2022","journal-title":"JAAD Case Rep"},{"issue":"5","key":"doi250022r15","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.jaci.2011.01.053","article-title":"Contrasting pathogenesis of atopic dermatitis and psoriasis\u2013part I: clinical and pathologic concepts.","volume":"127","author":"Guttman-Yassky","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"doi250022r16","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.jaci.2011.01.054","article-title":"Contrasting pathogenesis of atopic dermatitis and psoriasis\u2013part II: immune cell subsets and therapeutic concepts.","volume":"127","author":"Guttman-Yassky","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"doi250022r17","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.29","article-title":"Can atopic eczema and psoriasis coexist? a systematic review and meta-analysis.","volume":"1","author":"Cunliffe","year":"2021","journal-title":"Skin Health Dis"},{"issue":"7","key":"doi250022r18","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1080\/09546634.2019.1702147","article-title":"Concomitant atopic dermatitis and psoriasis - a retrospective review.","volume":"32","author":"Barry","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"doi250022r19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.coi.2017.08.008","article-title":"Atopic dermatitis and psoriasis: two different immune diseases or one spectrum?","volume":"48","author":"Guttman-Yassky","year":"2017","journal-title":"Curr Opin Immunol"},{"issue":"7","key":"doi250022r20","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1073\/pnas.1416922112","article-title":"IL-4 abrogates T(H)17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells.","volume":"112","author":"Guenova","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"doi250022r21","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1093\/rheumatology\/keaa568","article-title":"Regulation of entheseal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy.","volume":"60","author":"Bridgewood","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"doi250022r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2021.101520","article-title":"Unexpected connections of the IL-23\/IL-17 and IL-4\/IL-13 cytokine axes in inflammatory arthritis and enthesitis.","volume":"58","author":"Bridgewood","year":"2021","journal-title":"Semin Immunol"},{"issue":"6","key":"doi250022r23","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1136\/ard.2010.143123","article-title":"Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris.","volume":"70","author":"Bowes","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"doi250022r24","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1002\/art.42942","article-title":"Genetically proxied interleukin-13 inhibition is associated with risk of psoriatic disease: a mendelian randomization study.","volume":"76","author":"Zhao","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"doi250022r25","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jaad.2024.05.029","article-title":"Reduced atopic march risk in pediatric atopic dermatitis patients prescribed dupilumab versus conventional immunomodulatory therapy: a population-based cohort study.","volume":"91","author":"Lin","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi250022r26","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1016\/S2665-9913(23)00034-6","article-title":"Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study.","volume":"5","author":"Singla","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"9","key":"doi250022r27","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/jdv.18345","article-title":"European guideline (EuroGuiDerm) on atopic eczema: part I\u2014systemic therapy.","volume":"36","author":"Wollenberg","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"doi250022r28","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/all.14027","article-title":"New biological treatments for asthma and skin allergies.","volume":"75","author":"Eyerich","year":"2020","journal-title":"Allergy"},{"issue":"8","key":"doi250022r29","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/pds.3447","article-title":"Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009.","volume":"22","author":"Asgari","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"doi250022r30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098024","article-title":"Validity of diagnostic codes and prevalence of physician-diagnosed psoriasis and psoriatic arthritis in southern Sweden\u2014a population-based register study.","volume":"9","author":"L\u00f6fvendahl","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"doi250022r31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.5021\/ad.2020.32.2.115","article-title":"Validity of diagnostic codes for identification of psoriasis patients in Korea.","volume":"32","author":"Ham","year":"2020","journal-title":"Ann Dermatol"},{"issue":"1","key":"doi250022r32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","article-title":"Atopic dermatitis endotypes and implications for targeted therapeutics.","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"doi250022r33","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.anai.2023.11.020","article-title":"Diversity of atopic dermatitis and selection of immune targets.","volume":"132","author":"Rothenberg-Lausell","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"10281","key":"doi250022r34","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis.","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"doi250022r35","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1016\/j.jid.2022.03.013","article-title":"T helper 2 IL-4\/IL-13 dual blockade with dupilumab is linked to some emergent T helper 17\u2013type diseases, including seronegative arthritis and enthesitis\/enthesopathy, but not to humoral autoimmune diseases.","volume":"142","author":"Bridgewood","year":"2022","journal-title":"J Invest Dermatol"},{"issue":"4","key":"doi250022r36","doi-asserted-by":"publisher","first-page":"e296","DOI":"10.1111\/jdv.17050","article-title":"De novo psoriasis in atopic dermatitis patients treated with dupilumab: a retrospective cohort.","volume":"35","author":"Jaulent","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"doi250022r37","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s13555-021-00505-z","article-title":"Efficacy and safety of dupilumab in clinical practice: one year of experience on 165 adult patients from a tertiary referral centre.","volume":"11","author":"Napolitano","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"doi250022r38","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.jaad.2020.12.010","article-title":"Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis.","volume":"86","author":"Murphy","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi250022r39","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nm804","article-title":"Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease.","volume":"9","author":"Ghoreschi","year":"2003","journal-title":"Nat Med"},{"issue":"2","key":"doi250022r40","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/bjd.19459","article-title":"Increased expression of interleukin-23A in lesional skin of patients with atopic dermatitis with psoriasiform reaction during dupilumab treatment.","volume":"184","author":"Napolitano","year":"2021","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi250022r41","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/bjd.20064","article-title":"Dupilumab-induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin-17A expression: a case report.","volume":"185","author":"Mirza","year":"2021","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi250022r42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.893","article-title":"Comment on: development of psoriasis during treatment with dupilumab: a systematic review.","volume":"86","author":"Cohen","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi250022r43","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s41669-023-00459-2","article-title":"Cost-effectiveness analysis of abrocitinib compared with other systemic treatments for severe atopic dermatitis in Spain.","volume":"8","author":"Romero Jim\u00e9nez","year":"2024","journal-title":"Pharmacoecon Open"},{"issue":"6","key":"doi250022r44","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40257-023-00804-5","article-title":"Dupilumab-associated arthritis: a dermatology-rheumatology perspective.","volume":"24","author":"Woodbury","year":"2023","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"doi250022r45","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jaci.2019.01.015","article-title":"Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis.","volume":"144","author":"Zhou","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"doi250022r46","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.jaci.2015.08.015","article-title":"The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization.","volume":"136","author":"Noda","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"doi250022r47","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jaci.2018.06.016","article-title":"Atopic dermatitis in Chinese patients shows TH2\/TH17 skewing with psoriasiform features.","volume":"142","author":"Chan","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"doi250022r48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jdermsci.2010.02.008","article-title":"Extrinsic and intrinsic types of atopic dermatitis.","volume":"58","author":"Tokura","year":"2010","journal-title":"J Dermatol Sci"},{"issue":"2","key":"doi250022r49","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jaci.2013.04.046","article-title":"Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis.","volume":"132","author":"Su\u00e1rez-Fari\u00f1as","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"doi250022r50","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.jaci.2023.07.010","article-title":"The role of Janus kinase signaling in the pathology of atopic dermatitis.","volume":"152","author":"Guttman-Yassky","year":"2023","journal-title":"J Allergy Clin Immunol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2835236\/jamadermatology_lin_2025_oi_250022_1755630716.49448.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T15:00:37Z","timestamp":1755702037000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2835236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2025.1578","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}